Home > Healthcare > Analytical Instruments > Elemental Analysis > Label-free Array Systems Market

Label-free Array Systems Market Analysis

  • Report ID: GMI9649
  • Published Date: May 2024
  • Report Format: PDF

Label-free Array Systems Market Analysis

Based on technology, the market is classified into surface plasmon resonance, bio-layer interferometry, cellular dielectric spectroscopy, microcantilever, scanning kelvin nanoprobe, enthalpy array, atomic force microscopy, and other technologies. The surface plasmon resonance (SRP) segment is estimated to account for USD 669.2 million by the end of 2032.

  • SPR technology offers exceptional sensitivity and specificity in detecting and measuring biomolecular interactions. This makes it particularly useful for applications requiring precise quantification of binding affinities and kinetics, such as drug discovery, diagnostics, and biomolecular research.
  • It provides real-time monitoring of interactions without the need for labels. This real-time capability is crucial for understanding the dynamics of biomolecular interactions such as binding and dissociation rates, that are important in characterizing drug candidates and understanding biological processes.
  • Further, it is highly versatile and can be used to study a wide range of interactions, including protein-protein, protein-DNA, protein-small molecule, and cell-surface interactions. This versatility expands its applicability across various fields, including pharmaceuticals, biotechnology, and academic research.
  • SPR is a well-established and widely accepted technology in the scientific community. Its robust track record and extensive use in research and industry contribute to its dominant market position. Many researchers and institutions trust and rely on SPR for their experimental needs, thereby leading the segmental growth.

Label-free Array Systems Market, By Application (2023)

Based on application, the label-free array systems market is divided into drug discovery, protein interface analysis, antibody characterization and development, protein complex and cascade analysis, detection of disease biomarkers, and other applications. The drug discovery segment accounted for USD 483.6 million in 2023.

  • Drug discovery involves screening large libraries of compounds to identify potential drug candidates. Label-free array systems such as SPR and bio-layer interferometry (BLI), provide high-throughput screening capabilities, enabling researchers to quickly and efficiently identify promising compounds based on their binding affinities and kinetics.
  • The ability to conduct real-time analysis without the need for labeling reduces both the time and cost associated with drug screening. This efficiency is particularly valuable in the early stages of drug discovery, where large numbers of compounds must be tested rapidly and economically.
  • The quantitative data obtained from label-free array systems, such as kinetic rate constants and binding affinities are of high quality and crucial for making informed decisions in the drug development pipeline. These data help in understanding the potential efficacy and safety of drug candidates.
  • Further, modern label-free array systems are designed to integrate seamlessly with existing drug development workflows including automated sample handling and data analysis. This integration enhances productivity and allows for the efficient progression of drug candidates through the discovery pipeline.
  • Thus, such aforementioned factors are expected to enhance the segmental growth.

Based on end use, the label-free array systems market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, hospitals and clinics, and other end-users. The pharmaceutical & biotechnology companies segment held a market share of 38.3% in the year 2023.

  • These companies invest heavily in R&D to discover and develop new drugs and therapies. Label-free array systems are essential tools in this process, providing critical insights into biomolecular interactions, drug efficacy, and toxicity.
  • Pharmaceutical and biotechnology companies must generate reliable and reproducible data that meet regulatory standards. Label-free array systems provide high-quality data that can be used to support regulatory submissions and ensure compliance with industry standards.
  • Further, pharmaceutical and biotechnology companies are increasingly focusing on personalized medicine, developing treatments tailored to individual patients. Label-free array systems facilitate the study of patient-specific interactions, aiding in the development of personalized therapies.
  • Ongoing innovations in label-free technologies such as increased sensitivity, higher throughput, and improved data analysis capabilities, make these systems even more valuable to pharmaceutical and biotechnology companies. These advancements help drive their adoption and market share.

North America Label-free Array Systems Market, 2021 – 2032 (USD Million)

The U.S. label-free array systems market is anticipated to grow at CAGR of 6.9% during the analysis timeframe.

  • Increasing prevalence of chronic and infectious diseases is a significant factor for the growth of the market. For instance, according to the National Library of Medicine, in 2023, 1,958,310 new cases of cancer were diagnosed and 609,820 people died from the disease.
  • Further, as per American Diabetes, Association, in 2023, 37 million citizens were affected from diabetes including adults and youth. Thus leading to increased adoption of these systems and contributing to the substantial market share.

Germany label-free array systems market is anticipated to witness lucrative growth between 2024 – 2032.

  • The country is home to a robust biotechnology and pharmaceutical industry, with numerous companies engaged in drug discovery, development, and production. The presence of these industries drives the demand for advanced analytical technologies like label-free array systems.
  • German companies and research institutions are known for their willingness to invest in advanced technologies. This includes the adoption of state-of-the-art label-free array systems to enhance research capabilities and maintain a competitive edge in the global market.

Japan label-free array systems market is expected to grow significantly over the years.

  • Japan has a well-established biotechnology and pharmaceutical sector, with numerous companies engaged in cutting-edge research and development. This industry demands advanced analytical tools like label-free array systems to facilitate drug discovery, development, and production.
  • Additionally, the country is home to world-renowned universities and research institutions that conduct pioneering research in molecular biology, biochemistry, and related fields. These institutions rely on state-of-the-art label-free array systems to support their research activities.

UAE label-free array systems market is anticipated to witness lucrative growth between 2024 – 2032.

  • UAE government has made substantial investments in healthcare and biotechnology as part of its Vision 2021 and beyond. This strategic focus aims to diversify the economy and foster innovation, leading to increased demand for advanced technologies such as label-free array systems.
  • The country is rapidly developing its pharmaceutical and biotechnology sectors. With an increasing number of local and international companies setting up operations in the region, there is a heightened need for advanced analytical tools to support drug discovery and development efforts.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global label-free array systems industry size was valued at USD 1.4 billion in 2023 and is estimated to grow at 7.2% CAGR from 2024 to 2032 due to increasing drug discovery and development activities and rising cases of chronic and infectious diseases.

The surface plasmon resonance (SRP) segment in the market is estimated to account for USD 669.2 million by 2032 because SRP technology offers sensitive and label-free detection of biomolecular interactions.

The drug discovery segment of the label-free array systems market accounted for USD 483.6 million in 2023 due to screening large libraries of compounds to identify potential drug candidates and the ability to conduct real-time analysis.

Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Corning Incorporated, Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., Merck KGaA, Meso Scale Diagnostics (MSD), Nanion Technologies, and Pall Corporation, among others.

Label-free Array Systems Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 237
  • Countries covered: 23
  • Pages: 150
 Download Free Sample